Nebivolol
Bystolic · Nebilet · Lobivon
Half-life
10 hr
Time to Peak
1.5 hr
Steady State
~3 days
Dose Range
2.5–20 mg
Frequency
Daily
Overview
Third-generation, beta-1 selective adrenergic blocker. FDA-approved for hypertension. The TRT/AAS community specifically prefers nebivolol over other beta-blockers because it stimulates endothelial nitric oxide synthase (eNOS), producing vasodilation. This nitric oxide release partially counteracts the vasoconstrictive tendency of classic beta-blockers, preserving more of the pump and vascularity that users value during AAS cycles. Used to manage AAS-induced hypertension where standard first-line ARBs are insufficient or when heart rate control is needed alongside BP management. Harm reduction: Can cause fatigue and reduced exercise capacity at higher doses — start at 2.5–5mg. Not appropriate for users with significant bradycardia.
Mechanism of Action
Highly selective beta-1 adrenergic receptor antagonist. Unique among beta-blockers: also stimulates endothelial beta-3 receptors to release nitric oxide (eNOS pathway), causing peripheral vasodilation. Net effect: blood pressure reduction without the full vasoconstriction of first/second generation beta-blockers.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Oral | 2.5–20 mg | 10 hr | 1.5 hr | Daily |
Storage & Handling
Room temperature — Store at 20-25C. Protect from light.
Used in Regimens
Nebivolol is not currently part of any catalog regimen.
Data Sources
- FDA Label Bystolic (nebivolol) FDA Prescribing Information
Related Tools
Track Nebivolol with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.